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ABSTRACT
When the human health risk assessment/risk management paradigm was developed, it did not explicitly
include a ‘‘problem formulation’’ phase. The concept of problem formulation was first introduced in the
context of ecological risk assessment (ERA) for the pragmatic reason to constrain and focus ERAs on the
key questions. However, this need also exists for human health risk assessment, particularly for cumula-
tive risk assessment (CRA), because of its complexity. CRA encompasses the combined threats to health
from exposure via all relevant routes to multiple stressors, including biological, chemical, physical and
psychosocial stressors. As part of the HESI Risk Assessment in the 21st Century (RISK21) Project, a frame-
work for CRA was developed in which problem formulation plays a critical role. The focus of this effort
is primarily on a chemical CRA (i.e., two or more chemicals) with subsequent consideration of non-chem-
ical stressors, defined as ‘‘modulating factors’’ (ModFs). Problem formulation is a systematic approach
that identifies all factors critical to a specific risk assessment and considers the purpose of the assess-
ment, scope and depth of the necessary analysis, analytical approach, available resources and outcomes,
and overall risk management goal. There are numerous considerations that are specific to multiple stres-
sors, and proper problem formulation can help to focus a CRA to the key factors in order to optimize
resources. As part of the problem formulation, conceptual models for exposures and responses can be
developed that address these factors, such as temporal relationships between stressors and consider-
ation of the appropriate ModFs.
Abbreviations: AChE: acetylcholinesterase; ADI: acceptable daily intake; ADME: absorption, distribution,
metabolism, excretion; CRA: cumulative risk assessment; CCAG: common chemical assessment group;
EFSA: European Food Safety Authority; HESI: Health and Environmental Sciences Institute; ILSI:
International Life Sciences Institute; IVIVE: in vitro to in vivo extrapolation; IPCS: International Program on
Chemical Safety; NAS: United States National Academy of Sciences; NRC: National Research Council;
ModFs: modulating factors; PF: problem formulation; RfD: reference dose; RISK21: Risk Assessment in the
21st Century; TD: toxicodynamics; TK: toxicokinetics; USEPA: United States Environmental Protection
Agency; WHO: World Health Organization
ARTICLE HISTORY
Received 8 February 2016
Revised 30 June 2016
Accepted 7 July 2016
KEYWORDS
Cumulative risk assessment;
non-chemical stressors;
problem formulation;
RISK21; risk assessment
Table of contents
Introduction ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 836
RISK21 approach to cumulative risk ... ... ... ... ... ... ... ... ... 836
Background on PF ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 836
‘‘Gatekeeper’’ step ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 837
PF for CRA ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 838
Planning and scoping ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 838
Considerations specific to multiple stressors ... ... ... ... ... 839
Temporal relationships between stressors ... ... ... ... 839
Consideration of ModFs ... ... ... ... ... ... ... ... ... ... ... ... 839
Conceptual model ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 839
Exposure ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 840
Hazard ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 840
Receptors ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 840
Modulating factors ... ... ... ... ... ... ... ... ... ... ... ... ... ... 841
Plan for analysis for assessing cumulative risks ... ... ... ... 842
Conclusions ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 843
Acknowledgements ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 843
Declaration of interest ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 843
References ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 843
CONTACT Michelle R. Embry membry@hesiglobal.org ILSI Health and Environmental Sciences Institute, Washington, DC, USA
 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any
way.
CRITICAL REVIEWS IN TOXICOLOGY, 2016
VOL. 46, NO. 10, 835–844
http://dx.doi.org/10.1080/10408444.2016.1211617
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ità
 de
gli
 St
ud
i d
i M
ila
no
] a
t 0
0:4
7 0
5 S
ep
tem
be
r 2
01
7 
Introduction
A primary aim of risk assessment is informing decision makers
about the risks posed to public health by ‘‘real-world’’ envir-
onmental exposures to facilitate the weighing of these risks
against the benefits that accrue from the activities that gener-
ate the risk. Over time and with increased analytical sophisti-
cation, the complexity and diversity of real-world
environmental exposures to all types of stressors have
become increasingly apparent, necessitating a more holistic
approach to risk assessment; one that accounts for the com-
bined effects from exposure to both chemical and nonchemi-
cal stressors (Callahan & Sexton 2007; NRC 2009).
Cumulative risk assessment (CRA) is the term commonly
used for this process, the assessment of risks from com-
bined exposures. CRA has been described and developed in
numerous frameworks and reports (e.g., USEPA 2007; EFSA
2008, 2013; NRC 2009; Price et al. 2009, 2012; Meek et al.
2011). Some of the existing approaches are discussed in
some detail in Moretto et al. (2016). The problem formula-
tion (PF) phase is a shared activity between risk assessors
and risk managers as well as other stakeholders and, as
such, is a prerequisite before embarking on a risk assess-
ment (USEPA 2014). The present paper examines the key
issues involved in undertaking PF in the context of CRA,
and identifies analytical frameworks and conceptual models
that can help simplify the process and make the underlying
assumptions more explicit. The final product of the PF
phase should be a formal analytical plan that provides the
foundation for the subsequent assessment of cumulative
risks.
RISK21 approach to cumulative risk
The ILSI Health and Environmental Sciences Institute (HESI)
created the Risk Assessment in the 21st Century (RISK21) pro-
ject to address issues and catalyze improvements in human
health risk assessment. RISK21 has developed a conceptual
framework that is a PF-based, exposure-driven paradigm that
takes maximum advantage of existing information and aids in
identifying when additional data are needed to make a deci-
sion. The overarching principles of the RISK21 approach are
introduced by Pastoor et al. (2014) and explained in detail in
Embry et al. (2014).
The overall objective of the RISK21 CRA approach is to pro-
vide a process for assessing the possible adverse health
effects from combined exposure to multiple chemical and
non-chemical stressors. The companion paper (Moretto et al.
2016) describes the framework and approach in detail, follow-
ing the PF phase; however, it is important to note that cumu-
lative risk framework is not prescriptive. Rather the emphasis
is on documenting and supporting a logical rationale for why
a CRA is needed and under what restrictions, if any, the CRA
is being conducted. The scope of RISK21 CRA is limited to
multiple chemical stressors (i.e., two or more chemicals) with
subsequent consideration of non-chemical stressors, defined
as ‘‘modulating factors’’ (ModFs). Therefore, evaluations
focused only on non-chemical stressors or single chemicals
plus ModFs were considered out of scope.
The term ModFs was introduced in the RISK21 paper
describing a quantitative key events/dose–response frame-
work (Simon et al. 2014). The various factors that can modu-
late the effect of, or exposure to, a chemical (or both) were
separated into simpler elementary constituents. ModFs repre-
sent biological, environmental and lifestyle factors, including
host factors that can modulate the response to chemical
stressors, thus altering the probability or magnitude of the
adverse outcome. ModFs also include factors influencing
exposure, such as processing of food or weather patterns.
Their consideration in the PF step is further described in the
section ‘‘Consideration of modulating factors’’ and the meth-
odology for their inclusion in the RISK21 CRA framework is
discussed in detail in Moretto et al. (2016).
Background on PF
PF is a systematic approach that identifies all factors critical to
a risk assessment and considers the following elements:
 Purpose of the risk assessment;
 Overall risk management goal & options;
 Scope and depth of the analysis;
 Analytical approach and
 Available resources.
When the human health risk assessment/risk management
paradigm was first presented in 1983 (NAS 1983) it did not
explicitly include a PF phase. The concept of PF was first
introduced in the context of ecological risk assessment (ERA)
and in 1992, a PF step was incorporated in the framework for
ERAs (USEPA 1992) (Figure 1). More recently, the importance
of an explicit PF phase in risk assessment related to human
health and safety of food has also become more widely rec-
ognized (Renwick et al. 2003; NRC 2009; WHO 2009; WHO
IPCS 2009; Sheldon 2010) and this was a point stressed in
EPA’s recent Framework for Human Health Risk Assessment to
Inform Decision Making (USEPA 2014).
The first step in PF is defining the purpose or scope of the
assessment. This will set the boundaries for the assessment,
with the goal of making it ‘‘fit for purpose’’. For example, it
may be that a regulatory decision on a specific chemical
within a specific legislative category is needed and therefore,
the assessment should be limited to that chemical plus other
chemicals in that category. It could be that there is concern
about exposures from a single source, comprising a limited
but diverse range of chemicals. Or perhaps the concern is
about the totality of exposure to chemicals affecting a specific
biological process/target, such as the estrogen hormonal axis.
It is important to note that PF should be an iterative pro-
cess during which uncertainties (data gaps) are identified and
plans are made to address these. As key knowledge is refined
during the risk assessment, this informs reformulation of the
problem such that the risk assessment can proceed with the
degree of certainty and precision necessary to enable a deci-
sion to be made. This iteration may take place early or later in
the process when data on exposures and effects are better
understood but, in all cases, this should lead to a refinement
of the focus of the PF. In this context, it should be noted that
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exposures to some stressors may be more easily mitigated
than others and that, for some, mitigation may not be prac-
tical or possible. For this reason, an additional refinement of
the PF would be to consider options for risk management
early in the process and to focus on stressors that can, in fact,
be practically managed (see Table 7.1 of NRC 2009).
All PFs use existing information to characterize the stres-
sor(s) to be assessed and the population(s) or subgroup(s)
exposed to the stressor(s). For each stressor, this requires
knowledge of the determinants of the routes of exposure, the
frequency of exposures and the magnitude of exposure.
‘‘Gatekeeper’’ step
A prerequisite to PF in the CRA approach proposed by RISK21 is
a ‘‘gatekeeper’’ step, which determines whether CRA is war-
ranted. In reality, not all risk assessments will necessitate consid-
eration of multiple stressors. In many instances, completing a
full PF for CRA without first determining whether there is suffi-
cient evidence to support such an assessment would be a waste
of time and resources. Asking and answering the initial question,
‘‘In which circumstances and under what conditions is a CRA
necessary or even appropriate?’’ is extremely important.
A CRA is deemed not necessary or prudent if the totality
of information is such that it does not indicate evidence for
both co-exposure and common mode of toxic action or target
system. This step establishes a minimum set of conditions
that trigger the need for a CRA and requires that sufficient
evidence is available to justify moving into the full PF phase.
Figure 2 illustrates the proposed PF process for CRA, including
the addition of this initial ‘‘gatekeeper’’ step. A more detailed
description of the proposed RISK21 CRA Framework can be
found in Moretto et al. (2016).
Specifically, two key questions are proposed as part of the
gatekeeper step, to help guide the determination for a CRA.
1. If the currently available data demonstrate co-exposure, is
there a rationale for considering any of the compounds
in a common chemical assessment group (CCAG) based
on knowledge of toxicity?
CCAG is discussed in Moretto et al. (2016) and is defined
as a group of chemicals sharing both evidence for likeli-
hood of co-exposure within a relevant timeframe AND
evidence for dose-additive response at relevant human
exposure levels.
2. If the currently available data suggest or demonstrate
common toxicity, or any other reason to consider dose-
additivity is likely to occur, is there a rationale for consid-
ering any of the compounds in a CCAG based on know-
ledge of exposure?
Initial “gatekeeper”
step Sufficient initial evidence to support a CRA?
Planning & scoping Define purpose, endpoints, approach, and
depth
Consideration of
multiple stressor issues
Temporal relationships, relevant modulating
factors
Conceptual Models
Plan for Analysis Development of risk hypotheses, specification
of data needs and characterization approach
Exposure and effects
Figure 2. Schematic representation and description of the steps involved in PF
for CRA, including the ‘‘gatekeeper’’ step.
Formulate Objectives
Identify goals and objectives 
of risk management
Development of 
regulatory options
Identification of options 
for mitigation
Evaluation of public health, 
environmental, economic, social, 
and political consequences of 
regulatory options
RISK MANAGEMENTRISK ASSESSMENT
Planning and scoping
Identification and characterization of 
the stressors
Problem Formulation
Conceptual Model
Plan of Analysis
Characterization 
of Effects
Characterization 
of Exposures
Characterization of Risk
Analysis
Regulatory Decision
Figure 1. Diagrammatic representation of the processes of risk assessment and its relationship to risk management. Communication between the assessors and man-
agers (dashed arrows) and the iterative nature of the process is also illustrated (modified from USEPA 1992).
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A starting assumption of this framework approach is that
interactions are not likely to occur to a significant extent at
doses/exposure levels of individual chemicals at or below
their no-effect levels, and therefore only dose-additivity would
be expected for compounds with a similar mode of action
(Boobis et al. 2011; ECETOC 2011). Also, if any single chemical
is likely to be present at doses or concentrations above its
health-based guidance values, such as its reference value, or
any other appropriate value (e.g., TTC for data-poor com-
pounds), it would be premature to start a CRA until the risk
from that individual chemical had been addressed.
The data used to complete this gatekeeper step should be
carefully documented and integrated into the overall PF.
Scientific evidence should therefore be assembled such that a
transparent determination can be made concerning the likeli-
hood of co-exposure AND the likelihood of common toxicity
for all chemicals being considered. Both pieces of information
are requisite to justify the need to assess cumulative risk and
are emphasized as part of this step, which establishes a min-
imum set of conditions that trigger the need for a CRA and
requires that sufficient evidence is available to justify moving
into the full PF phase.
It is stressed that this gatekeeper step does not involve a
complete assessment but rather represents an initial collection
and summary of the data in-hand for the purpose of formulat-
ing the problem of CRA. Given a sufficient rationale can be
established via available evidence on likelihood of co-expos-
ure AND common toxicity, a full PF should ensue. There is no
need for tiers at the gatekeeper stage, they will be applied
during the CRA procedure following the PF.
PF for CRA
PF for CRA is a stepwise process (Figure 2) and is described in
detail in the following sections.
Many risk assessments are conducted within a specific con-
text that involves regulators and a number of stakeholders
who have an interest in the issue in question. The USEPA
Framework for CRA (USEPA 2003) and the WHO IPCS (Meek et
al. 2011) recommend that planning and scoping of the risk
assessment (Figure 1) should begin with a dialog among
these individuals or groups. This dialog should be two-way
and may be iterative as the PF is refined, the plan of analysis
is developed, and the resources required for the assessment
are identified.
Planning and scoping
In the planning and scoping stage, it is important to carefully
define the terms of reference (ToR) of the CRA. These will
comprise the focus of the risk assessment and the key ques-
tions to be addressed. The ToR should be such that the CRA
will provide relevant, science-based evidence to answer the
concerns of decision makers and other stakeholders, in an
appropriate time-frame and within the available resources.
This should be a formal and transparent process and the
approaches used to identify these key questions and concerns
need to be documented. In this sense, the PF is the refine-
ment and translation of questions from decision makers and
various stakeholders into scientifically testable hypotheses.
A key activity in the planning and scoping phase is to
clearly identify the goals for protecting human health and/or
the environment and the endpoints used to determine risk or
harm. These ‘‘protection goals’’ are usually defined in the vari-
ous statutes and regulations that relate to the protection of
human health and the environment and, although these differ
somewhat between jurisdictions, the main objective is the
protection of the individual, a population, or an ecosystem
against a specific risk or against any harm. However, the
meaning of ‘‘protection’’ and ‘‘harm’’ is subject to interpret-
ation and, whilst a laudable social and/or political objective it
may be hard to define numerically or even qualitatively (e.g.,
is mild sensory irritation harm?) and therefore it may be diffi-
cult to determine if the level of protection is adequate or if
mitigation measures have actually improved the situation.
Often, implicit levels of protection are used, based on regula-
tory exposure limits (assessment endpoints), i.e., if exposure is
below the RfD or ADI, the desired level of protection has
been achieved.
Assessment endpoints are actual measures against which
protection can be evaluated. They are predicated on the
(implicit) protection goals but are quantitative so that they
can be easily combined and/or compared in a mathematical
sense. In keeping with the objectives of assessing risks to
humans from exposures to multiple chemical stressors, end-
points that could be used in the CRA are those that are cur-
rently used in various regulations; however, attention must be
paid to the population at risk and the predicted route of
exposure. For example, if only oral ingestion is expected, end-
points of concern via the dermal route of exposure would be
irrelevant. In the case of chemical stressors for which stand-
ards or other regulatory decisions exist, the endpoints will
have been identified in toxicity testing of the individual chem-
icals and extrapolated to humans for the purposes of setting
of guidelines for exposures from air, food and water. These
limits may reflect a probability of risk (e.g., the often-
employed 1 in 106 estimate for cancer risk) or application of a
set of extrapolation factors for responses that have, or are
more likely to have, a threshold and/or are readily reversible.
Endpoints for ModFs are less well defined. While it would
be possible to include easily-quantified measures of the
physical environment, such as temperature, humidity and
intensity of noise as assessment endpoints, this would be
much more difficult for the psychosocial environment, nutri-
tion or infectious diseases. However, where these are influenc-
ing or contributing to exposure or the responses to chemical
stressors, the assessment endpoints for the chemicals can be
used.
As has been pointed out (Moretto et al. 2016), CRA should
be conducted using a tiered approach. This allows stressors
that truly do not present or do not significantly contribute to
a cumulative risk to be eliminated from consideration early in
the process and helps to simplify the assessment by reducing
the number of hypotheses that need to be tested. The frame-
work for cumulative risks from chemicals proposed by IPCS
(Meek et al. 2011) serves as a starting point. It should be
pointed out that this process is tiered and that it may not be
838 K. R. SOLOMON ET AL.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ità
 de
gli
 St
ud
i d
i M
ila
no
] a
t 0
0:4
7 0
5 S
ep
tem
be
r 2
01
7 
necessary to complete all of the tiers to reach a decision. For
instance, Tier 0 data may be sufficient to conduct a CRA
based on worst-case assumptions of exposure and interaction
which demonstrates an acceptable level of risk, as defined by
the PF, eliminating the need for further consideration or
assessment. However, if multiple tiers of information are
required, the assessment endpoint remains the same.
Considerations specific to multiple stressors
PF differs for single and multiple stressors. PFs for single sub-
stances may involve many considerations but are manageable
to carry out. However, PFs for combinations of chemicals and
ModFs could become orders of magnitude more complex
and, perhaps, even unworkable. Thus, what is needed is the
appropriate information to identify the boundaries within
which the risk of the combined exposures can be accepted
and not necessarily a complete description of all the charac-
teristics of the stressors in question. Whilst important for a
single stressor, it is critical for multiple stressors that the PF
efficiently narrows the focus of the assessment to the key
issues and questions, and bounds the uncertainties. This
should be done with a view to the desired goal of the assess-
ment in light of actions that can be taken for risk manage-
ment which will have a real impact.
For a CRA, the factors identified in the initial PF lead to a
conceptual model which organizes the linkages and manages
the assessment. For example, the probability of co-occurrence
of exposures that would lead to cumulative effects must be
considered (see below). This requires an understanding of the
spatial distribution of the stressors and their temporal co-
occurrence, at least within the time-frame for the causation of
cumulative responses. Based on such considerations, it may
be possible to eliminate some stressors from further discus-
sion, thus reducing complexity.
For chemical stressors, information of how they may inter-
act in the exposed population or subgroup should be identi-
fied, if possible. For this, knowledge of the mechanisms and/
or mode of action of the stressors as well as their toxicody-
namics (TD) and toxicokinetics (TK) might become essential if
higher tiered assessment is needed. Key data on TK include
distribution and (lack of) persistence of the substances in
organs or tissues. This provides information on which tem-
poral co-occurrence in potential target organs can be
assessed and can help reduce the number of hypotheses on
interactions that need to be considered. Key information on
TD includes the time-course of recovery and the potential for
joint action (additive or otherwise). Both TK and TD may be
modified by other stressors.
The complexity of the assessment can vary markedly with
the needs of the risk manager, and will depend on the policy
context. This should be clearly identified in PF. Additional con-
siderations that must be taken into account when dealing
with multiple stressors are described below.
Temporal relationships between stressors
Timing of exposures to multiple stressors is a major determin-
ant of risks of adverse responses to combined exposures.
Traditionally, contemporaneous (co-)exposure to two or more
stressors has been used as the trigger for considering additive
or other interactive effects. However, consecutive, separate or
partially overlapping exposures may also be important. For
some responses, particularly interactive responses or those
mediated via ModFs, prior exposures may be more important
than simultaneous exposure. This, in turn, will be influenced
by the duration of the response, any latency of response to
the stressor(s) and rate of recovery from the effects of the
stressor(s) (Figure 3). The influence of temporality of
responses and recovery is but one pathway for cumulative
interactions. Recovery may be very rapid (hours), such as for
carbamylated AChE, longer (days-weeks) for phosphorylated/
aged AChE, or even transgenerational, such as for some gen-
etic or epigenetic changes that modify TD or TK. This last
point is important as stressors, such as famine, have resulted
in epigenetic changes in humans that may affect interactive
response in one generation (Koturbash et al. 2011; Maze et al.
2011; Smeester et al. 2011) or be transgenerational (Anway
et al. 2005; Painter et al. 2006; Skinner et al. 2011; Vanhees
et al. 2011).
Consideration of ModFs
There is an additional level of complexity in CRA when ModFs
must be considered and/or some of the chemicals do not
cause effects through traditional toxicological mechanisms. In
the context of initiatives on environmental justice, it has been
recommended to include social, economic, cultural and com-
munity health factors, especially those involving vulnerability,
into CRA frameworks (NEJAC 2004, 2010). Obviously, ModFs
on their own can also interact to cause cumulative effects,
but the focus of this paper is directed to situations where
more than one chemical has been identified as an issue.
Nevertheless, the concepts discussed here should also be use-
ful in providing guidance for PF for combinations of stressors
acting only by non-toxicological mechanisms.
ModFs fall into four main categories: host factors, lifestyle,
environmental factors and other chemicals (Table 1). These
need to be considered in detail during the later stages of the
CRA process (Moretto et al. 2016), but during the PF phase,
an initial appraisal should be included in the conceptual
model (see section ‘‘Modulating factors’’).
Conceptual model
For PFs developed for single or multiple stressors that are
known (i.e., the hazards have been identified), the outcome of
the process consists of a conceptual model, a series of risk
hypotheses that can then be tested with the data that have
been gathered, and a plan of analysis. The conceptual model
for exposure defines the routes, amounts, frequency, intensity,
and, in the case of CRAs, the probability of co-occurrence of
the stressors. The conceptual model for effects in the exposed
(sub)groups includes the effects of the individual stressors
and how these may combine to result in additive responses.
Responses other than additivity, i.e., antagonistic, or synergis-
tic, for combined chemical exposures should not be an issue
since these generally occur only at biologically effective doses
CRITICAL REVIEWS IN TOXICOLOGY 839
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(Boobis et al. 2011; SCHER, SCCS, SCENIHR 2012). Possible
exceptions may occur in certain instances with the ‘‘effect
based’’ approach, when one or more components are present
above their threshold (limit). Since there will be little or no
information in humans on many of the potential interactions,
extrapolation of effects observed in experimental systems
(e.g., IVIVE) to humans may be required. The development of
the model will likely be iterative, as long as any of the data
used to develop the model are refined. The conceptual model
provides the basis for the risk hypotheses, which may be
related to different subgroups including different life-stages or
(patho)physiological conditions, stressors, exposure scenarios
and responses which can then be tested with the data on
exposures and effects.
Exposure
The movement and fate of chemicals in the environment and
how humans may be exposed to them is relatively well
understood. Examples of potential sources of chemical stres-
sors are manufacturing, combustion of fossil fuel and/or bio-
mass, treatment of waste, agricultural activities, extraction of
mineral resources, activities in the home, etc. (Figure 4). If
these chemicals are used, either in a process, or released to
the environment they may move from the point of release to
result in exposures of humans. Ultimately, these routes of
exposure will be via air, soil, water, solids carried in air or
water, and food.
Exposures may be via a single route (i.e., dermal, inhalation
or oral) or they may be aggregated over several routes which
may vary over time and space, even for a single chemical, but
particularly important for cumulative assessments. For chem-
ical stressors, their physicochemical properties will be major
drivers of their movement in the environment and route of
exposure.
Hazard
The key to construction of a useful and practical conceptual
model of effects is to be able to quantify the relationship
between exposures to the chemical stressors, relevant ModFs
and response. Exposures to multiple chemical stressors may
result in cumulative responses via TK and/or TD processes.
The former, i.e., the absorption, distribution, metabolism and
excretion of one or more xenobiotic, is a key determinant of
the type and magnitude of response. This will lead to a cer-
tain combined concentration at the target site (e.g., organo-
phosphate insecticides) (Timchalk & Poet 2008). Knowledge of
the mode of action and ADME will provide guidance to help
identify potential interactions. In the spectrum of interactions
from cumulative effects of pharmaceuticals and other stres-
sors, there is a wealth of data on TK and TD and how effects
on these processes may alter responses to other pharmaceuti-
cals, but at biologically effective doses. In the context of envir-
onmental exposure at low levels it is important to first
establish whether TK and/or TD interactions are to be
expected. It should also be noted that interactive effects may
not necessarily be adverse in that they may stimulate detoxifi-
cation of other substances or act antagonistically via TD
mechanisms. In addition, components of food, such as sec-
ondary metabolites of plants, may affect TK (Alvarez et al.
2010; Jin & Han 2010) and TD of chemical stressors (Friedman
2006).
Receptors
In the case of human health risk assessments, receptors may
be the population as a whole, individuals or groups of people,
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Ex
po
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 a
nd
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on
se
Stressor 1
Stressor 2
Recovery
Cumulave 
response 
Temporal co-occurrence of exposures with
addive or interacve response
Response to 
stressor 1
No temporal co-occurrence of exposures but with addive or
interacve response in the period of recovery from stressor 1
Cumulave 
response
Time
No temporal co-occurrence of exposures and
independent responses with no interacon
Response to 
stressor 1 Response to 
stressor 2
Figure 3. Diagrammatic representation of temporal differences in exposures and how these may interact with persistence of the stressor in the organism and/or
latency of response or length of recovery from the stressor. Examples: (A) a mixture of a carbamate and organophosphorus insecticides, (B) an organophosphorus
insecticide followed by a carbamate and (C) a carbamate followed by an organophosphorus insecticide. While this representation may not apply to apical end-points, it
may help understanding and visually describing the need for CRA when an intermediate KE occurs, although, when considering an individual compound, no clear
apical effect is observed. In the example provided, AChE can be inhibited at subthreshold levels by each individual compound, but, depending on timing, the threshold
can be reached (overcome) after combined exposure. Heavy black lines – exposure; shaded areas – response.
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e.g., specific age groups such as children or the elderly; sus-
ceptible populations with preexisting disease, such as asthma;
occupational groups; residents of a specific area; ethnic
groups; economically disadvantaged groups, or subsets of the
population with specific sensitivity mediated by genetic or
epigenetic factors. Thus, in Figure 4, the arrows can be modi-
fied as appropriate (e.g., bolded or dashed) to indicate that
exposures may be of different intensity and some or many
may not be relevant and could therefore be excluded from
the assessment. The task in construction of the conceptual
model is to assign appropriate quantities and/or intensity to
the various potential routes of exposure and effects. This will
then facilitate identification of the key questions and hypothe-
ses of risks from exposures and responses to multiple stres-
sors to be ranked and prioritized.
Modulating factors
ModFs can be grouped into host factors, life-style factors,
environmental factors and other chemicals (Table 1). As previ-
ously discussed, these factors, if deemed necessary for inclu-
sion, must be considered in detail in the CRA process
(Moretto et al. 2016) but should also form part of the concep-
tual model in the PF phase. Given the complexity of these
assessments, and the consequences of compounding multiple
conservative assumptions, the number of variables to be con-
sidered should be kept to a minimum. In any case, it is
important that the process is transparent and clearly commu-
nicated; an explanatory narrative should accompany the pro-
posed table and associated graphical visualization (see below)
of the effects of the ModFs.
Host factors Some of these factors will affect the types of
stressor to which humans are exposed, the intensity, and the
responses. It is important to note that the vulnerability of
humans to exposure and effects may differ across groups as a
consequence of differences in genetic make-up, preexisting
diseases, defense mechanisms and physiology.
Life-style factors Nutritional stressors, such as obesity, starva-
tion or deficiency of essential vitamins or micronutrients
should be considered because they may interact with other
stressors via alteration of physiological and biochemical
processes.
Pharmaceuticals are separated from chemical and non-
chemical stressors because exposures are deliberate and they
are taken by humans because of their beneficial effects on
health. In addition, the use of these substances is usually
linked to preexisting diseases, infections, parasites and psy-
chological stressors. As these substances are taken in doses
that do alter physiological and biochemical processes, they
are more likely to alter the TK and/or TD of other stressors
Sources of chemical
stressors
Environmental
repositories
Release to
atmosphere during
use
Air
Applicaon or use
Soil, dust, surfaces
Treatment of waste
Food
Spills or accidental
release
Groundwater
Water
Potenal
modulang factors
Host factors
Lifestyle factors
Environmental factorsTo
xi
co
dy
na
m
ic
s
To
xi
co
ki
ne
c
s
Humans Receptor
Movement in the
environment
Figure 4. Generic conceptual model for cumulative risk.
Table 1. Modulating factors.
Category Sub-category Aspects
Host factors
Genetic Variation Polymorphisms
Disease/Illness ChronicAcute
Defense mechanisms
Immune responsiveness
DNA repair
Cell proliferation
Cell death
Physiology
Gender
Life stage, age, development
ADME
Hormonal status
Life-style 
factors
Diet Calories, fat content, deficiencies
Dietary supplements Vitamins and anti-oxidants
Exercise Frequency and/or intensity
Pharmaceuticals Usage
Tobacco and alcohol Usage
Illegal drugs Usage
Environmental 
factors
Occupation Duration
Other stressors
Other chemicals
Air pollutants
Psychological and mental
Temperature
Socioeconomic
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(see below), as has been observed in the case of adverse
reactions to combinations of drugs.
Environmental factors Physical stressors include temperature
(heat or cold), various forms of radiation (UV and X-rays and
c-radiation), noise and vibration. All of these have the poten-
tial to affect processes in the organism that may alter TK and/
or TD of chemical stressors.
Psychological stressors and their potential interactions with
human health have been summarized in an editorial (Barkin &
Schlundt 2011) where it is proposed that a cascade of exter-
nal factors such as the geophysical, economic, political, com-
munity and interpersonal environments may interact with the
psychology of an individual to affect physiological and bio-
chemical processes in the body with the end result that
response to a stressor is altered. They further point out that,
to identify, categorize and quantify these stressors, a
multidisciplinary team will be needed with expertise in many
areas.
Socioeconomic stressors may also be important and can
act directly or indirectly. In the former case, for example, a
lack of access to health care could result in a background of
poor health that may exacerbate adverse effects from chemi-
cals as well as biological agents. In the latter, socioeconomic
stressors may exacerbate psychological, nutritional, disease
stressors as well as increase exposures to chemical stressors.
For instance, an index can be created for racial/ethnic and
socio-economic inequalities (Su et al. 2009), or for social deter-
minants (Salinas et al. 2012). Matrices (WHO 2010) and algo-
rithms (NEJAC 2010; Zartarian et al. 2011; USEPA 2016;
Hastings et al. 2013) have been developed to help identify
highest comparative risks. It is recognized that this requires
additional types of scientific expertise and demands rigorous
methodology for a clear delimitation of the analysis so that it is
manageable and provides meaningful and applicable results.
Other chemicals Chemical ModFs can impact the toxicity of a
single chemical under consideration, or multiple chemical
stressors for which the CRA is focused via TK, TD or both
(Wason et al. 2012). For this reason, inclusion of ModFs will be
highly dependent on available data and may serve to elevate
the complexity of the assessment.
When determining the inclusion/exclusion of ModFs which
are also chemicals, it must be stressed that the effects of the
ModFs should occur and be relevant at or below the refer-
ence point/point of departure. ModFs, specifically, other
chemicals that are not included in the CCAG, that are relevant
at large doses (experimental doses that are several orders of
magnitude higher than the human exposure levels) but irrele-
vant at human exposures should not be included in the CRA.
There are several examples of ModFs occurring at large doses,
only. These include, among others, saturation of metabolic
pathways, saturation of excretory processes, consumption of
buffering systems, and overload of repair systems. Examples
include the hepatotoxicity of acetaminophen, which occurs
only after glutathione levels in the liver are depleted
(Henderson et al. 2000); the pulmonary toxicity of paraquat,
which occurs only after renal excretion becomes saturated
(Lock & Wilks 2010).
Plan for analysis for assessing cumulative risks
The final step in the process of PF is the development of the
plan for the analysis of the risks posed by the exposures and
effects identified in the conceptual models. The results of the
conceptual models will identify a number of questions related
to the assessment of risk of chemicals and ModFs. These
include:
1. Which groups will be exposed and to what exposures?
2. What is the duration and frequency of exposures?
3. Within the constraints of the window of temporality that
is important for CRA, what is the probability of co-occur-
rence of exposures?
4. What are the measures of effect for the mixture of
stressors?
5. Do the stressors act additively or is there evidence for
more or less than additive effects at environmentally-rele-
vant exposures?
Based on these questions, a plan of analysis should specify
which data are to be collected and how they are to be charac-
terized. As discussed in Embry et al. (2014), different amounts
of data will be required for different tiers. Lower tiers based on
deterministic hazard quotients require few data but are usually
very conservative. Higher tiers such as probabilistic character-
izations require extensive modeling or measurements or a
combination of both. The hypotheses of risk are thus tested
with the data on exposures and effects. These hypotheses can
range from simple comparisons of deterministic values for
exposures and effects via a quotient (with uncertainty factors)
to full probabilistic analysis as discussed in Pastoor et al. (2014).
Among the factors that need to be considered when
developing a plan of analysis are the strengths of the meth-
ods of the test or model and their underlying data, their rele-
vance to the problem that is being investigated, and
uncertainties concerning the scenarios, theoretical assump-
tions and data obtained.
Strength addresses the inherent quality of a test (or com-
puted data) relating to the methodology of the test or model,
and the way that the performance and results of the test or
model are described. Testing and modeling data in hazard
assessment can be realized through many different
approaches and conditions, e.g., for testing data: standardized
protocol or not, test design, analytical method, mixture of
compounds, statistical methodology, etc.; for modeling data:
homogeneity of data, outliers, modeling techniques, etc.
Exposure information can also be based on different models
and assumptions and the reliability of existing approaches/
tools depends on factors such as definition of exposure scen-
arios; selection of exposure routes; etc.
Relevance covers the extent to which a data set is appro-
priate for a particular risk assessment. The objective is to pro-
vide a comprehensive overview of all the factors taken into
account for characterizing and ranking the relevance of data
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respective to a given assessment context and to build a rele-
vance consensus framework.
Uncertainty can be analyzed according to its sources in all
risk assessments, i.e., variability and lack of knowledge, and
the types of uncertainty. For CRA, key areas of uncertainty
are:
1. Uncertainty in the decision-rule, e.g., choice of chemi-
cals to include in assessment group, selection of
ModFs, choice of exposure scenarios, choice of uncer-
tainty factors for extrapolations, handling of conflicting
evidence;
2. Uncertainty in the structure, e.g., false positive or false
negative assumptions, such as the nature of the com-
bined effect of chemicals in an assessment group, homo-
geneity and description of the compartment,
extrapolation for other species, extrapolation from route
to route, statistical models applied and
3. Uncertainty in the parameters, e.g., temporality of expos-
ure, temporality of effects, number of replicates, emission
measurements, measurements on partitioning and con-
centration in various media, physico-chemical data.
Such a classification is a prerequisite for a better mutual
understanding of the confidence attributed to a given
dataset.
Conclusions
PF is an iterative process in which preliminary hypotheses are
developed about the possible occurrence of adverse effects
as a consequence of exposure to multiple chemicals and
ModFs. It provides the foundation for the technical approach
to the subsequent risk assessment. The outcome of the PF
process is a conceptual model, or models, that identify the
stressors, exposure pathways, the population exposed and the
protection goal/assessment endpoints that will be covered in
the risk assessment, and which describes the relationships
among them (USEPA 2003).
One of the key challenges of PF in a CRA is the need to
adequately define the relative importance of different stres-
sors with regard to their effect on endpoints of concern. Here,
an early assessment of the temporal relationship between
exposures to various stressors is a critical step, as is determin-
ing whether there is a likelihood of interaction between them,
or in their effect on specific endpoints.
PF in CRA is essential to ensure that assessments under-
taken are relevant to public health, and that they can be
achieved in a realistic timeframe with the resources avail-
able. It is important that PF focuses the assessment on the
basis of those risk mitigation strategies that are feasible
and likely to have significant impact. Early identification of
relevant chemicals to form the CCAG and potential ModFs
during PF will ensure that the advice provided based on
the CRA results will have the most utility for decision mak-
ing. Through well-constructed and well-conducted PF, it
should be possible to undertake CRA in a timely and
informative way, so that the output is of real value to risk
managers.
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